Biopsy and re-biopsy for PD-L1 expression in NSCLC. association between PD-L1 and checkpoint inhibitor efficacy through treatment in NSCLC. A pilot study.
Pavlos ZarogoulidisDimitris PetridisHaidong HuangChong BaiWolfgang Hohenforst-SchmidtLutz FreitagSofia BakaDimitris DrougasAnastasios VagionasKosmas TsakiridisJ Francis TurnerDimitris HatzibougiasIoannis BoukovinasBojan ZaricTomi KovacevicAris IoannidisNikolaos CourcoutsakisDimitris MatthaiosChrisanthi SardeliPublished in: Expert review of respiratory medicine (2021)
The findings of this study suggest that the PD-L1-65 index works adequately either concerning the neo-metastatic sites or the patient disease responses. Re-biopsies in new metastastic sites are necessary since we probably have a new cancer and chemotherapy should be added. More studies should confirm are results and change the NSCLC treatment approach of these patients.
Keyphrases
- small cell lung cancer
- advanced non small cell lung cancer
- ultrasound guided
- squamous cell carcinoma
- newly diagnosed
- ejection fraction
- prognostic factors
- papillary thyroid
- fine needle aspiration
- young adults
- oxidative stress
- radiation therapy
- epidermal growth factor receptor
- replacement therapy
- cell proliferation
- rectal cancer
- chemotherapy induced